The Swedish BioFINDER Study
The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.
News articles
A drop of blood can detect Alzheimer’s – international award
The 2026 Jeffrey L. Morby Prize has been awarded to researchers from Lund University and Washington University for a...
Read more...New blood biomarker reduces the risk of misdiagnosing Alzheimer’s disease.
The new blood tests for diagnosing Alzheimer’s disease are providing increasingly better opportunities for early diagnosis, but one challenge...
Read more...
Recent key publications
- 9 April, 2026
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum.
- 31 March, 2026
A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia
- 18 March, 2026
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer’s disease: a prospective cohort study
- 16 March, 2026
Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling
X posts
New paper in Nature Aging led by PhD student @LuLina000147323! We mapped how APOE ε4 and APOE ε2 shape molecular changes in blood and cerebrospinal fluid across Alzheimer’s disease.
Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease
Nature Aging - Apolipoprotein E (APOE) is the strongest genetic influence in Alzheimer’s disease (AD). Compared to ...
www.nature.com
Using large-scale proteomics across multiple cohorts, we found that APOE ε4 and APOE ε2 have largely distinct protein signatures. Many changes appeared even before detectable Aβ pathology, suggesting that APOE-related molecular alterations may begin long before dementia develops.
A big thanks to all authors and collaborators!
@LuLina000147323, @ines_hristovska, @cumplido_irene, @anlijuncn, @RikOssenkoppele, @SebastianPalmqv, @_JakeVogel_, @EStomrud, @NiklasMattsson4
New paper in Nature Communications! We mapped trajectories of multiple tau species in plasma & CSF across the AD continuum. Different tau species change at distinct stages: %p-tau217 earliest, MTBR-tau243 later, highlighting stage-specific biology.
🔗
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s...
Nature Communications - Plasma and CSF p-tau biomarkers show similar dynamics across Alzheimer’s disease progression, ...
www.nature.com
Big thanks to all authors and collaborators! @LECollij @gesalbla @KantaHorie @tobeybetthauser @ErikRubenSmith @SebastianPalmqv @SuzanneESchind1 @RikOssenkoppele @NiklasMattsson4 @RandallBateman3
New publication alert!
Are patients seen in primary care eligible for amyloid-targeting therapies (ATT) for treatment of Alzheimer’s disease? 🧠We evaluated ATT eligibility among patients with cognitive symptoms in primary care in southern Sweden.
Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms
Alzheimer's Research & Therapy - Alzheimer’s disease (AD) is the most common cause of dementia and a growing hea...
link.springer.com
This study was led by Beata Borgström Bolmsjö. A big thanks to all collaborators and co-authors: @DaniellevWe @SuzanneESchind1 @LECollij @ErikRubenSmith @NiklasMattsson4 @EStomrud @SebastianPalmqv and all not on X.